Evidence map›Paper›PMID 40658162›Full record

ArticleClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2026

High FSTL1 expression promotes bladder cancer progression by enhancing tumor cell migration.

Helin Zhang, Xingxing Zhang, Yuelin Du, Wei Xiong, Xiaojun Zhang, Biao Zhang, Panfeng Shang

Abstract read
PubMed Publisher
In one paragraph

Article in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Helin ZhangThe Second Hospital and Clinical Medical School, Lanzhou University, No. 82 Cui Ying Gate, Cheng Guan District, Lanzhou, 730000, Gansu, China.
Xingxing ZhangThe Second Hospital and Clinical Medical School, Lanzhou University, No. 82 Cui Ying Gate, Cheng Guan District, Lanzhou, 730000, Gansu, China.
Yuelin DuThe Second Hospital and Clinical Medical School, Lanzhou University, No. 82 Cui Ying Gate, Cheng Guan District, Lanzhou, 730000, Gansu, China.
Wei XiongThe Second Hospital and Clinical Medical School, Lanzhou University, No. 82 Cui Ying Gate, Cheng Guan District, Lanzhou, 730000, Gansu, China.
Xiaojun ZhangThe Second Hospital and Clinical Medical School, Lanzhou University, No. 82 Cui Ying Gate, Cheng Guan District, Lanzhou, 730000, Gansu, China.
Biao ZhangThe Second Hospital and Clinical Medical School, Lanzhou University, No. 82 Cui Ying Gate, Cheng Guan District, Lanzhou, 730000, Gansu, China.
Panfeng ShangThe Second Hospital and Clinical Medical School, Lanzhou University, No. 82 Cui Ying Gate, Cheng Guan District, Lanzhou, 730000, Gansu, China. shangpf@lzu.edu.cn.ORCID http://orcid.org/0000-0002-9622-9664

Funding

This study was supported by a grant from the Cuiying Science and Technology Innovation Program of the Second Hospital of Lanzhou University No. CY2021-QN-A13This study was supported by a grant from the Cuiying Science and Technology Innovation Program of the Second Hospital of Lanzhou University NO. CY2024-MS-A02
6 · The paper itself

Abstract

objectiveEmerging evidence highlights diverse roles of FSTL1 across various malignancies, though its biological significance in bladder carcinogenesis remains unexplored.

methodsThis study systematically interrogated FSTL1 using multidimensional bioinformatics approaches-including tumor microenvironment characterization, survival pattern evaluation, and differential expression profiling-through multiple bladder cancer datasets from TCGA and GEO repositories, with subsequent experimental validation employing in vitro cellular models.

resultsOur findings demonstrate that FSTL1 exhibits significant overexpression in bladder tumors, promotes cancer cell motility through pro-migratory mechanisms, and potentially modulates key components of the tumor microenvironment.

conclusionFSTL1 might be a therapeutic target or biomarker for the advancement of bladder cancer.

Indexed as

Cell MovementFollistatin-Related ProteinsUrinary Bladder NeoplasmsBiomarkers, TumorCell Line, TumorDisease ProgressionGene Expression Regulation, NeoplasticHumansTumor MicroenvironmentBiomarkers, TumorFollistatin-Related ProteinsFSTL1 protein, humanBiomarkerBladder cancerFSTL1ProgressionTherapeutic targetTumor microenvironment

Identifiers

PMID40658162

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.